An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo
Description
Prophylactic vaccines for SARS-CoV-2 have lowered the incidence of severe COVID-19, but emergence of viral variants that are antigenically distinct from the vaccine strains are of concern and additional, broadly acting preventive approaches are
